Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.

Skin cells can naturally limit the growth of cancerous changes by balancing cell renewal and differentiation.

Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.

The apelinergic system might protect the heart from damage caused by doxorubicin.

Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.

Scalp cooling significantly reduces hair loss in chemotherapy patients.

The study concludes that the EDA2R gene is activated by p53 during chemotherapy but is not necessary for chemotherapy-induced hair loss.

These new skin treatments are safer and more effective with minimal side effects.

Cancer treatments often cause hair loss, and more research is needed to prevent and treat it.

Alpha-difluoromethylornithine prevents cancer in mice but causes hair loss.

Radiation therapy for cancer often causes skin problems like redness, dryness, and pain.

ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.

New cancer treatments aim to reduce side effects and improve effectiveness.

Adjusting the medication tacrolimus resolved a boy's red nail beds after a stem cell transplant.

Radiotherapy is a good option when further surgery for skin cancer isn't preferred, but more research is needed to compare it with other methods.

A patient with complete hair loss regrew all her hair using tofacitinib.

BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

TheDES improve drug delivery through the skin but need more safety checks.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

TB and BCC tumors show similar follicular differentiation patterns.

Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.

Aromatase inhibitors can cause skin issues, especially with anastrozole and exemestane, so monitoring is important.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.